Moreover, synthetic lethality screens conducted in human AML cells harboring FLT3-ITD mutations have found a number of metabolic genes (e.g., ATM and G6PD) able to sensitize FLT3-ITD cells to FLT3 inhibitors [6]. The gene discussed is FLT3; the disease is acute myeloid leukemia.